| Latest | F'cast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% | 
| Div Cover | n/a | n/a | 
| Op Mrgn | n/a | n/a | 
| ROCE | n/a | 
| Latest | F'cast | |
|---|---|---|
| P/E | n/a | n/a | 
| PEG | n/a | n/a | 
| Pr/Revenue | n/a | n/a | 
| Pr/Book | 3.3 | 
| Latest | F'cast | |
|---|---|---|
| Revenue | n/a | n/a | 
| PBT | n/a | n/a | 
| EPS | n/a | n/a | 
| DPS | n/a | n/a | 
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield | 
|---|---|---|---|---|---|---|---|---|
| 31-Dec-20 | n/a | (2.67) | 0.00¢ | n/a | n/a | n/a | n/a | 0.0% | 
| 31-Dec-21 | n/a | (1.79) | (0.13)¢ | n/a | n/a | n/a | n/a | 0.0% | 
| 31-Dec-22 | n/a | (2.61) | (0.19)¢ | n/a | n/a | n/a | n/a | 0.0% | 
| 31-Dec-23 | 0.04 | (0.20) | (1,225.00)p | n/a | n/a | n/a | n/a | 0.0% | 
| 31-Dec-24 | n/a | (0.59) | (0.01)p | n/a | n/a | n/a | n/a | 0.0% | 
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| US Orphan Drug Designation Application | 30-Oct-2025 | 07:00 | RNS | 
| Positive Preclinical Data in Prostate Cancer | 14-Oct-2025 | 07:00 | RNS | 
| Half Year Report | 15-Sep-2025 | 07:00 | RNS | 
No deals were found in the last 28 days.
| Currency | UK Pounds | 
| Share Price | 12.00p | 
| Change Today | 0.000p | 
| % Change | 0.00 % | 
| 52 Week High | 12.80 | 
| 52 Week Low | 12.00 | 
| Volume | 3,050 | 
| Shares Issued | 39.96m | 
| Market Cap | £4.80m | 
| Value | 
		 | 
		
|---|
| Value | 
		 | 
		
|---|
| Income | ![]()  | 
				
|---|
| Growth | ![]()  | 
				
|---|
| Latest | Previous | |
|---|---|---|
| Special | Interim | |
| Ex-Div | 01-Jun-23 | n/a | 
| Paid | 14-Jun-23 | n/a | 
| Amount | 1.80p | 0.000¢ | 
| Time | Volume / Share Price | 
| 08:06 | 3,050 @ 12.80p | 
| CEO | Andrew James Webb | 
You are here: research